SCHEMBL230198

SCHEMBL230198

CC(=O)CCCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.71
LMNA P02545 3/20 0.71
NFKB1 P19838 1/20 0.71
PMP22 Q01453 1/20 0.71
SLC15A2 Q16348 1/20 0.63
GPR84 Q9NQS5 8/20 0.62
PPARG P37231 7/20 0.62
PPARD Q03181 7/20 0.62
PPARA Q07869 7/20 0.62
HDAC11 Q96DB2 5/20 0.62
PTPN1 P18031 3/20 0.62
ALDH1A1 P00352 2/20 0.62
TLR2 O60603 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
FABP4 P15090 2/20 0.62
FFAR1 O14842 2/20 0.62
FFAR4 Q5NUL3 2/20 0.62
SLC22A6 Q4U2R8 1/20 0.62
SLC22A8 Q8TCC7 1/20 0.62
MEN1 O00255 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348686 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL561614 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL2350916 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL2346452 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL2348213 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL2989964 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL24538421 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL2350035 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL15903953 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2
SCHEMBL2346285 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22SLC15A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3000846-B1 POLYESTER RESIN COMPOSITION AND MOLDED ARTICLE INCLUDING RESIN COMPOSITION KANEKA CORP (JP) 2019-02-20 EP claimed
US-4274987-A ESTERIFIED HYDROXY OR ACETYL FATTY ACIDS NL INDUSTRIES, INC. (US) 1981-06-23 US claimed
WO-2025003023-A1 METHOD FOR PRODUCING A CARBOXYLIC ACID EVONIK OPERATIONS GMBH (DE) 2025-01-02 WO disclosed
EP-3000846-B1 POLYESTER RESIN COMPOSITION AND MOLDED ARTICLE INCLUDING RESIN COMPOSITION KANEKA CORP (JP) 2019-02-20 EP disclosed
WO-2017197048-A1 ALBUMIN BINDING CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME AMUNIX OPERATING INC. (US) 2017-11-16 WO disclosed
EP-2279417-B1 METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF GEORGIA TECH RES INST (US) 2016-07-20 EP disclosed
EP-3000846-A1 POLYESTER RESIN COMPOSITION AND MOLDED ARTICLE INCLUDING RESIN COMPOSITION Kaneka Corporation (JP) 2016-03-30 EP disclosed
EP-2948507-A1 POLYLACTIC ACID COMPOSITION, AND PRODUCTION METHOD AND PRODUCTION APPARATUS OF THE SAME Ricoh Company, Ltd. (JP) 2015-12-02 EP disclosed
WO-2014115486-A1 POLYLACTIC ACID COMPOSITION, AND PRODUCTION METHOD AND PRODUCTION APPARATUS OF THE SAME RICOH COMPANY, LTD. (JP) 2014-07-31 WO disclosed
US-20120004854-A1 METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF GEORGIA TECH RESEARCH CORPORATION 2012-01-05 US disclosed
EP-1544190-B1 METHOD FOR PRODUCING CARBOXYLIC ACIDS NAT INST OF ADVANCED IND SCIEN (JP) 2011-08-31 EP disclosed
EP-2279417-A1 METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF Georgia Tech Research Corporation (US) 2011-02-02 EP disclosed
WO-2009151967-A1 METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF GEORGIA TECH RESEARCH CORPORATION (US) 2009-12-17 WO disclosed
US-7186858-B2 Method for producing carboxylic acid NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2007-03-06 US disclosed
US-20050215817-A1 Method for producing carboxylic acid NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2005-09-29 US disclosed
EP-1544190-A1 METHOD FOR PRODUCING CARBOXYLIC ACID National Institute of Advanced Industrial Science and Technology (JP) 2005-06-22 EP disclosed
EP-0498372-B1 Sustained-release pranoprofen preparation SS PHARMACEUTICAL CO (JP) 1996-10-09 EP disclosed
EP-0498372-A1 Sustained-release pranoprofen preparation SS PHARMACEUTICAL CO., LTD. (JP) 1992-08-12 EP disclosed
US-4274987-A ESTERIFIED HYDROXY OR ACETYL FATTY ACIDS NL INDUSTRIES, INC. (US) 1981-06-23 US disclosed
US-4210572-A POLYOXYALKYLENE GLYCOLS ETHERIFIED WITH A HYDROXY-FATTY ACID AS SURFACTANT NL INDUSTRIES, INC. (US) 1980-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215817-A1 Method for producing carboxylic acid ADH1C, HAO2, ALDH2 TSHR 2104/4885LMNA 3596/4885NFKB1 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.